Mesoblast Limited (ASX: MSB) Share Price and News
Price
Movement
(20 mins delayed)
52 Week Range
-
1 Year Return
Mesoblast Limited Chart and Price Data
Fundamentals Data provided by Morningstar.
Share Price
Day Change
52 Week Range
-
Yesterday's Close
Today's Open
Days Range
-
Volume
Avg. Volume (1 month)
Turnover
as at 24 Feb 3:44pm
Mesoblast Limited (ASX: MSB)
Latest News
Share Gainers
Why ARB, Mesoblast, Pushpay, & Super Retail shares are racing higher
Share Market News
5 things to watch on the ASX 200 on Tuesday
Share Market News
ASX 200 drops 0.9%
Share Market News
Mesoblast (ASX:MSB) share price soars 14% on clinical trial results
⏸️ ASX Shares
These are the 10 most shorted shares on the ASX
Share Market News
Mesoblast (ASX:MSB) share price could be facing more pressure in 2021
Share Market News
Do ASX mining companies carry the Australian share market?
⏸️ ASX Shares
These are the 10 most shorted shares on the ASX
⏸️ ASX Shares
These are the 10 most shorted shares on the ASX
Share Fallers
Why Mesoblast, Monash IVF, Netwealth, & Reece shares are dropping lower
Share Gainers
Why a2 Milk, Air New Zealand, Mesoblast, & Recce shares are storming higher
Best Shares
7 top ASX biomedical shares in 2020
Frequently Asked Questions
-
No, Mesoblast does not pay shareholder dividends at this time.
-
Yes, Mesoblast is listed on the ASX and the US Nasdaq under the ticker code NASDAQ: MESO.
-
Mesoblast Ltd listed on the ASX on 16 December 2004.
MSB ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|---|---|---|---|---|
| YesNo |
About Mesoblast Limited
Mesoblast Ltd (ASX: MSB) is a clinical-stage biotechnology company. It develops and commercialises allogeneic cellular medicines to treat complex diseases resistant to conventional standards of care.
Its portfolio of Phase 3 product candidates includes its flagship remestemcel-L for the treatment of steroid-refractory acute graft versus host disease (SR-aGVHD) as well as moderate to severe acute respiratory distress syndrome (ARDS). Its other candidates include REVASCOR® for advanced chronic heart failure and MPC-06-ID for chronic low back pain due to degenerative disc disease. These cell therapy candidates are towards the latter stages of their clinical trial pipelines.
Mesoblast has locations in Australia, the United States, and Singapore and is dual-listed on the ASX and the US Nasdaq (NASDAQ: MESO).
